Advancing The Cardiovascular Care in Cancer Patients on Chemotherapy

Muhammad Yamin, Simon Salim, Muhammad Syahrir Azizi, Lusiani Rusdi, Aru Wisaksono Sudoyo, Anneira Amanda Putri


Cardiotoxicity associated with chemotherapy, also known as Cancer Therapy-Related Cardiac Dysfunction (CTRCD), affects 10% of patients undergoing chemotherapy and is the most undesirable side effect of chemotherapy. Over time, it is anticipated that there would be an increase in the number of cancer patients receiving treatments that could harm their cardiovascular systems. Physicians should choose whether to continue, halt, delay, or reduce the dose of chemotherapeutic drugs to reduce the impact of cardiotoxicity.
Cardiotoxicity screening and diagnosis need a variety of methods, primarily echocardiography to evaluate Left Ventricular Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS). Depending on the clinical state, these procedures may be carried out prior to, during, or following chemotherapy. It’s critical to reduce cardiovascular risk factors and offer advice on leading a healthy lifestyle before giving cancer patients medicines.
There are a lot of cancer treatment facilities all around the world that don’t have evidence-based perspective cardiotoxicity scores to stratify the risk of cardiovascular problems caused by cancer therapy. Additionally, comorbid conditions like diabetes and hypertension are frequently present in cancer patients, which can have a significant impact on clinical outcomes and cancer treatment. Therefore, this article aims to discuss assessment methods, clinical practice guidance, and prevention of CTRCD.


cardiac disease; cardiotoxicity; CTRCD; chemotherapy; cancer


Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(2):171–90.

The Global Cancer Observatory. GLOBOCAN 2020. 2020 [cited 2022 Dec 26]; Available from:

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - PubMed [Internet]. [cited 2023 Jun 30]. Available from:

Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.

World Health Organization. Indonesia Source GLOBOCAN 2018: GLOBOCAN sources and methods. 2018; Available from:

Peng J, Rushton M, Johnson C, et al. An international survey of healthcare providers’ knowledge of cardiac complications of cancer treatments. Cardio-Oncol Lond Engl. 2019;5:12.

Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.

Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(8):893–911.

Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: An overview for the clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445.

Esquivias GB, Asteggiano R. Cardiac management of oncology patients: Clinical handbook for cardio-oncology. 2015:1.

McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75.

Virani SA, Dent S, Brezden-Masley C, et al. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol. 2016;32(7):831–41.

Virizuela J, Martín-García A, de las penas R, et al. SEOM clinical guidelines on cardiovascular toxicity (2018). Clin Transl Oncol. 2019;21.

Af Y, B K. Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart Br Card Soc [Internet]. 2016 Mar [cited 2023 Jun 30];102(6). Available from:

Huszno J, Leś D, Sarzyczny-Słota D, Nowara E. Cardiac side effects of trastuzumab in breast cancer patients – single centere experiences. Contemp Oncol. 2013;17(2):190–5.

Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017;47(8):678–82.

Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2014;27(9):911–39.

Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306.

Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603.

Tajiri K, Bando H, Tasaka N, et al. Echocardiographic myocardial strain imaging and troponin t for early detection of cardiotoxicity in patients receiving anthracyclines. J Am Coll Cardiol. 2019;73(9_Supplement_1):801.

Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J. 2011;38(3):263–5.

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.